Abstract
Background: Thyroid hormone (T3) is essential for normal development of children enabling brain development and somatic growth. However, certain individuals are genetically predisposed with insufficient or no thyroid hormones. Such a condition is termed congenital hypothyroidism (CH).
Objective: In the present review, a brief back ground about congenital hypothyroidism, factors associated with CH leading to thyroid dysgenesis and thyroid dyshormonogenesis is elaborated. Additionally, the guidelines for available treatment options, management and follow-up required for patients diagnosed with CH are discussed. Treatment options in terms of treatment initiation and dosage of hormone replacement are discussed. Conclusion: Though CH is considered as the most common neonatal metabolic disorder, it is also easily treatable compared to other metabolic or hereditary diseases. The outcome of CH treatment depends on the compliance of parents early in life and by patients themselves during later part of life.Keywords: Congenital hypothyroidism, hormone therapy, levothyroxine, thyroid gland, transcription factors, Thyroid hormone (T3).
Current Pharmaceutical Design
Title:Congenital Hypothyroidism: Facts, Facets & Therapy
Volume: 23 Issue: 16
Author(s): Yedukondalu Kollati, Ranga Rao Ambati, Prakash Narayana Reddy, N. Satya Sampath Kumar, Rajesh K. Patel*Vijaya R. Dirisala*
Affiliation:
- Sandor Animal Biogenics Private Limited, Sandor Life Sciences, Telangana-500043,India
- Department of Biotechnology, Vignan’s Foundation for Science, Technology and Research University (VFSTRU), Guntur-5222, Andhra Pradesh,India
Keywords: Congenital hypothyroidism, hormone therapy, levothyroxine, thyroid gland, transcription factors, Thyroid hormone (T3).
Abstract: Background: Thyroid hormone (T3) is essential for normal development of children enabling brain development and somatic growth. However, certain individuals are genetically predisposed with insufficient or no thyroid hormones. Such a condition is termed congenital hypothyroidism (CH).
Objective: In the present review, a brief back ground about congenital hypothyroidism, factors associated with CH leading to thyroid dysgenesis and thyroid dyshormonogenesis is elaborated. Additionally, the guidelines for available treatment options, management and follow-up required for patients diagnosed with CH are discussed. Treatment options in terms of treatment initiation and dosage of hormone replacement are discussed. Conclusion: Though CH is considered as the most common neonatal metabolic disorder, it is also easily treatable compared to other metabolic or hereditary diseases. The outcome of CH treatment depends on the compliance of parents early in life and by patients themselves during later part of life.Export Options
About this article
Cite this article as:
Kollati Yedukondalu, Ambati Rao Ranga, Reddy Narayana Prakash, Kumar Satya Sampath N., Patel K. Rajesh*, Dirisala R. Vijaya*, Congenital Hypothyroidism: Facts, Facets & Therapy, Current Pharmaceutical Design 2017; 23 (16) . https://dx.doi.org/10.2174/1381612823666170206124255
DOI https://dx.doi.org/10.2174/1381612823666170206124255 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tetracyclic Triterpenoids in Herbal Medicines and their Activities in Diabetes and its Complications
Current Topics in Medicinal Chemistry Stem Cell Therapy for the Treatment of Acute Myocardial Infarction and Chronic Ischemic Heart Disease
Current Pharmaceutical Biotechnology The Significance of Renal Function in Response to Cardiac Resynchronisation Therapy – A Piece of a Much Larger Puzzle
Current Vascular Pharmacology Effects of Metabolic Approach in Diabetic Patients with Coronary Artery Disease
Current Pharmaceutical Design Prognostic Role of miRNAs in Coronary Artery Disease
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Dev elopment (Part C))
Current Pharmaceutical Design Usefulness of 5 Minutes <sup>123</sup>I-mIBG Scan in Parkinson’s Disease and Heart Failure
Current Radiopharmaceuticals A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry ALDH2---The Genetic Polymorphism and Enzymatic Activity Regulation: Their Epidemiologic and Clinical Implications
Current Drug Targets Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Administration of Exogenous Surfactant and Cytosolic Phospholipase A2α Inhibitors may Help COVID-19 Infected Patients with Chronic Diseases
Coronaviruses Thienopyridines in Percutaneous Coronary Interventions: Standard Procedures and High Risk Subsets
Current Pharmaceutical Design Focal Adhesion Kinase: From In Vitro Studies to Functional Analyses In Vivo
Current Protein & Peptide Science Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention
Current Drug Targets Evaluation of Gene and Cell-Based Therapies for Cardiac Regeneration
Current Stem Cell Research & Therapy From Amino Acids to Proteins as Targets for Metal-based Drugs
Current Drug Metabolism Treatment of Takotsubo Cardiomyopathy
Current Pharmaceutical Design Gemcitabine-Related Atrial Fibrillation: A Case Report and Review of the Literature
Current Drug Safety Targeting the Chemokines in Cardiac Repair
Current Pharmaceutical Design